Merck and Bayer's heart drug vericiguat meets primary efficacy endpoint in Phase 3 study
March 28, 2020 at 11:50 AM EDT
Merck & Co Inc said on Saturday that vericiguat, an investigational drug for patients with worsening chronic heart failure, met the primary efficacy endpoint in the VICTORIA trial.
